Equations (11)–(12) — unique sales-based best response
ProvedRareDisease.Endogenous.best_response_Abest-responsep2o-batch-pfp2ap2o-gran-per-chapterp2o-plan-paperp2o-v1sales-based-paymentsubsidy
Let be the R&D cost scale and let be a subsidy policy. In Setting (1A), where the manufacturer chooses price and target efficacy and is paid per sale, its complete best-response set is
Thus equations (11) and (12) give the unique joint price and efficacy choice, rather than merely one stationary point.
Formalization Note Manufacturer choices range over and , as in the game definition; the paper does not impose .
Preamble
import Mathlib import Definitions.Def_RareDisease_Endogenous_Setting
Formal statement
namespace RareDisease.Endogenous
/-- Equations (11)–(12), p. 12: the joint sales-based best response is unique. -/
theorem best_response_A (k α β : ℝ) (hk : 0 < k) (hpolicy : IsPolicy α β) :
BRA k α β = {
(1 / (16 * (1 - α) * k * (1 - β) ^ 2),
1 / (8 * (1 - α) * k * (1 - β)))} := by sorry
end RareDisease.Endogenous
Source
Olsder, Martagan, Tang, Improving Access to Rare Disease Treatments: Optimal Subsidies, Pricing, and Payment, SSRN working paper 3481150 (version of 2019-11-13), p. 12, §4.1, equations (11)–(12)
Human review
Confirmed by the mission captain (proposal self-audit).
Confirmed by the moderator at approval.